Last reviewed · How we verify

Anemia Working Group Romania — Portfolio Competitive Intelligence Brief

Anemia Working Group Romania pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tinzaparin administration Tinzaparin administration marketed
Heparin administration Heparin administration marketed Anticoagulant Antithrombin III (indirect); Thrombin and Factor Xa (downstream targets) Cardiovascular
continuation (darbepoetinum) continuation (darbepoetinum) marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  2. Amgen · 1 shared drug class
  3. Beijing Chao Yang Hospital · 1 shared drug class
  4. Australian and New Zealand Intensive Care Research Centre · 1 shared drug class
  5. Barts & The London NHS Trust · 1 shared drug class
  6. Beijing Anzhen Hospital · 1 shared drug class
  7. Ain Shams University · 1 shared drug class
  8. Affymax · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Anemia Working Group Romania:

Cite this brief

Drug Landscape (2026). Anemia Working Group Romania — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anemia-working-group-romania. Accessed 2026-05-16.

Related